An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy
Circulation · 20.10.2026 · 154 (16) · 1592-1603
DOI: 10.1161/circulationaha.126.080302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 20.10.2026. Verfasst von Elizabeth Jordan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine (E.J., P.P., J.C., R.E.H.), The Ohio State University, Columbus. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Evidence of the diverse genetic architecture of dilated cardiomyopathy (DCM) continues to emerge and requires reassessment of the clinical relevance of implicated disease genes. Building on the 2019-2020 Clinical Genome Resource evaluation, the DCM gene curation expert panel reconvened in 2024-2025 to conduct a reassessment of genes in DCM. METHODS: The Clinical Genome Resource semiquantitative clinical validity classification framework was applied with specifications to DCM to classify genes into categories on the basis of strength of published evidence for a DCM phenotype. Previously curated genes were reassessed, and newly reported gene–disease–mode of inheritance (MOI) relationships, termed “curations,” were evaluated. RESULTS: Sixty-eight genes were evaluated, inclusive of 72 unique gene-disease-MOI relationships across 51 previously evaluated and 17 newly assessed genes. Thirty-five curations were classified as high evidence (16 Definitive, 10 Strong, 9 Moderate), increasing by 16 from the prior assessment. Nine newly assessed genes were classified as high evidence: BAG5 , FLII , LMOD2 , MYLK3 , MYZAP , NRAP , PPA2 , PPP1R13L , and RPL3L . Twelve genes (11 newly appraised) were rated as high evidence with an autosomal recessive (AR) MOI. Five reevaluated genes from 2019-2020 had clinically significant changes in classification. Except for JPH2 , for which curation was modified to separate autosomal dominant and AR MOI curations, clinically significant changes involved upgrades from low- to high-evidence categories ( PLEKHM2 , PRDM16 , TBX20 , TNNI3K ), demonstrating the robustness of the Clinical Genome Resource gene curation process over time. An additional 29 gene-disease-MOI curations were classified as Limited, including 6 newly evaluated genes and 1 new MOI for a previously evaluated gene, MYBPC3 -AR; 4 were classified as No Known Disease Relationship, and remained Disputed. Four previously evaluated genes were curated for both AD and AR MOIs: JPH2 (AD-Strong, AR-Limited), LDB3 (AD-Limited, AR-Strong), MYBPC3 (AD-Limited, AR-Limited), and TNNI3 (AD- and AR- Strong). CONCLUSIONS: With substantial new evidence, the genetic architecture of DCM has rapidly expanded. This updated assessment of genes reported in DCM yielded 35 high-evidence curations, an increase from 19 only 5 years ago. The results of this evidence-based evaluation process inform clinical interpretation of genetic information in the care of DCM patients and families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine (E.J., P.P., J.C., R.E.H.), The Ohio State University, Columbus.
- The Davis Heart and Lung Research Institute (E.J., P.P., J.C., R.E.H.), The Ohio State University, Columbus.
- Department of Medicine, Duke University Hospital, Durham, NC (P.G.).
- Department of Medicine, Johns Hopkins University, Baltimore, MD (B.A., E.B., C.A.J., B.M.).
- Department of Clinical Laboratory Medicine, Juntendo University, Chiba, Japan (T.A.).
- Cardiovascular Genomics Center, Inova Heart and Vascular Institute, Falls Church, VA (A.B.).
ORCID-Profile: Elizabeth Jordan, Patricia Parker, Jason Cowan, Babken Asatryan, Tomohiko Ai, Akos Berthold, Emily Brown, Rudy Celeghin, Matthew Edwards, Cynthia A James, Renee Johnson, Daniel P Judge, Sean Jurgens, Najim Lahrouchi, Tom Lumbers, Francesco Mazzarotto, Argelia Medeiros Domingo, Stacey Peters, Kalliopi Pilichou, Petros Syrris, Jessica Wang, Roddy Walsh, James S Ware, Ray E Hershberger
Zitieren
APA
Jordan, E., Grover, P., Parker, P., Cowan, J., Asatryan, B., Ai, T., Berthold, A., Bronicki, L., Brown, E., Celeghin, R., Edwards, M., Fan, J., James, C. A., Johnson, R., Judge, D. P., Jurgens, S., Lahrouchi, N., Lumbers, T., Mazzarotto, F., …, & Hershberger, R. E. (2026). An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy. Circulation, 154(16), 1592-1603. https://doi.org/10.1161/circulationaha.126.080302
Vancouver
Jordan E, Grover P, Parker P, Cowan J, Asatryan B, Ai T, et al. An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy. Circulation. 2026;154(16):1592-1603. doi:10.1161/circulationaha.126.080302
BibTeX
@article{Jordan2026,
author = {Jordan, Elizabeth and Grover, Phoenix and Parker, Patricia and Cowan, Jason and Asatryan, Babken and Ai, Tomohiko and Berthold, Akos and Bronicki, Lucas and Brown, Emily and Celeghin, Rudy and Edwards, Matthew and Fan, Judith and James, Cynthia A and Johnson, Renee and Judge, Daniel P and Jurgens, Sean and Lahrouchi, Najim and Lumbers, Tom and Mazzarotto, Francesco and Medeiros Domingo, Argelia and Murray, Brittney and Peters, Stacey and Pilichou, Kalliopi and Protonotarios, Alexandros and van Spaendonck-Zwarts, Karin and Syrris, Petros and Wang, Jessica and Walsh, Roddy and Ware, James S and Hershberger, Ray E},
title = {An Updated Evidence Assessment of the Genetic Causes of Dilated Cardiomyopathy},
journal = {Circulation},
year = {2026},
volume = {154},
number = {16},
pages = {1592--1603},
doi = {10.1161/circulationaha.126.080302}
}
EUVIMED